JEMPERLI in combination with carboplatin and paclitaxel offers meaningful study results For people with newly-diagnosed advanced or returned endometrial cancer

JEMPERLI + carboplatin and paclitaxel (CP): The FIRST AND ONLY FDA-approved immunotherapy combination proven to help patients with newly-diagnosed advanced or returned endometrial cancer LIVE LONGER.*

*In the overall study population, median overall survival (OS) with JEMPERLI + CP was 45 months vs 28 months with CP alone. This difference is statistically significant, which means that the difference between the two treatment groups is greater than what might be expected by chance alone. Median (MEE-de-un) is the middle value in a set of measurements. OS measures the average length of time patients are alive after the start of treatment. JEMPERLI + CP was not studied in comparison to other immunotherapy combinations.

How JEMPERLI was studied in patients like you

A clinical trial compared JEMPERLI + CP versus CP alone in 494 people with endometrial cancer that had spread outside the uterus (newly-diagnosed advanced) or returned, also known as the overall study population. The overall study population included people whose tumors were either dMMR/MSI-H or MMRp/MSS.

dMMR stands for “mismatch repair deficient.” It describes cancers that have an MMR system that is not working properly to correct errors in the genes. MSI-H, or microsatellite instability-high, describes unstable genes in some tumors that may occur because the MMR system is not repairing mistakes properly. MMRp, or mismatch repair proficient, describes cancers that have an MMR system that is working properly to correct errors in the genes. MSS, or microsatellite stable, describes cancers that have stable genes because the MMR system is working properly to correct errors in the genes. These are important biomarkers in endometrial cancer.

Person with lightbulb icon

Study participants taking JEMPERLI + CP received:

500 mg of JEMPERLI + CP every 3 weeks for 6 doses

Then 1000 mg of JEMPERLI alone every 6 weeks

Gray person icon

Study participants taking CP alone received:

CP + placebo (an inactive substance designed to look like the medicine being tested) every 3 weeks for 6 doses

Then placebo alone every 6 weeks

Why this may be important to you

The clinical trial tested the effectiveness and safety of adding JEMPERLI to CP. The trial treated some patients with JEMPERLI + CP and others with a placebo (an inactive substance) + CP and then compared the results. Based on the results of this trial, this combination of medications was approved by the U.S. Food and Drug Administration (FDA) and made available for doctors to prescribe to patients.

Overall population tag

People receiving JEMPERLI + CP with newly-diagnosed advanced or returned endometrial cancer LIVED LONGER

Overall survival (OS): The average length of time patients are alive after the start of treatment.

In the overall study population, median OS with JEMPERLI + CP was 45 months vs 28 months with CP alone. This difference is statistically significant, which means that the difference between the two treatment groups is greater than what might be expected by chance alone. Results varied among different biomarker groups within the overall population. Median is the middle value in a set of measurements. JEMPERLI + CP was not studied in comparison to other immunotherapy combinations.

JEMPERLI + CP significantly extended OS

JEMPERLI + CP overall survival vs CP alone

136 out of 245 participants treated with JEMPERLI + CP were still alive, compared with 105 out of 249 treated with CP alone.

OS gold standard measure banner

People taking JEMPERLI + CP lived a median of 16 MONTHS LONGER than those taking CP alone

Median is the middle value in a set of measurements.

Median OS:

Median OS results for JEMPERLI + CP vs CP alone

Patients receiving JEMPERLI + CP were significantly less likely to have their cancer grow, spread, or get worse compared to CP alone

Progression-free survival (PFS): Measures a delay or pause in disease progression or refers to the length of time that study participants experienced without their cancer growing, spreading, or getting worse.

In the overall study population, participants receiving JEMPERLI + CP experienced a median of 12 months without their cancer growing, spreading, or getting worse, compared with 8 months for those on CP alone. This difference is statistically significant, which means that the difference between the two treatment groups is greater than what might be expected by chance alone. Results varied among different biomarker groups within the overall population. Median is the middle value in a set of measurements.

Study participants receiving JEMPERLI + CP were:

Progression-free survival results for JEMPERLI + CP vs CP alone

110 out of 245 participants treated with JEMPERLI + CP didn’t experience their cancer growing, spreading, or getting worse, compared with 72 out of 249 treated with CP alone.

dMMR/MSI-H tag

People with dMMR/MSI-H biomarker status taking JEMPERLI + CP experienced a median of 30 months without their cancer growing, spreading, or getting worse

The JEMPERLI clinical trial also measured median progression-free survival (PFS) in people with dMMR/MSI-H tumors. PFS is the length of time that participants experienced without their cancer growing, spreading, or getting worse. Median (MEE-de-un) is the middle value in a set of measurements.

Median PFS results for people with dMMR/MSI-H biomarker status taking JEMPERLI + CP vs CP alone

37 out of 60 participants treated with JEMPERLI + CP didn’t experience their cancer growing, spreading, or getting worse, compared with 15 out of 62 treated with CP alone.

Document with magnifying glass icon

Study participants receiving JEMPERLI + CP were 71% less likely to have their cancer grow, spread, or get worse compared with those receiving CP alone.

Overall population tag

Objective response rate for JEMPERLI + CP compared to CP alone

Objective response rate (ORR): The percentage of people in a study whose tumors partially shrink or disappear in response to the treatment within a certain period of time.

JEMPERLI + CP:

Response rates in the RUBY trial for JEMPERLI when given with CP

This does not always mean that the cancer has been cured.

CP Alone:

Response rates in the RUBY trial for placebo when given with CP

You are not alone

Endometrial cancer statistics

About 61,000 cases of endometrial cancer are diagnosed annually in the US

About 1 in 4 people with endometrial cancer has cancer that has come back after treatment or has spread outside the uterus (advanced cancer)

Light bulb icon

What is JEMPERLI?

JEMPERLI is an immunotherapy. This means it is designed to work with the body’s immune system to help fight cancer.

Learn How It Works

Exclamation point in triangle icon

What are the side effects of JEMPERLI?

Certain side effects have been observed in people taking JEMPERLI. While everyone’s treatment experience is different, knowing what you may expect can help.

See Risks and Side Effects

Download icon

Resources for you

Knowledge is power. That’s why we’re committed to providing you with educational resources to help you stay informed along your treatment journey.

Go to Resources

Related FAQs

  • How many people participated in the clinical trial of JEMPERLI in combination with carboplatin and paclitaxel?

    There were 494 patients included in the clinical trial that studied the effectiveness of JEMPERLI in combination with the chemotherapy medicines, carboplatin and paclitaxel, compared to carboplatin and paclitaxel alone. They had endometrial cancer that was newly-diagnosed and had spread outside the uterus (advanced) or had returned.

    The clinical trial also studied the risks and side effects of JEMPERLI in combination with the chemotherapy medicines, carboplatin and paclitaxel, in 241 people with newly diagnosed advanced or returned endometrial cancer.

  • What is a biomarker?

    A biomarker (BY-oh-MAR-ker) is a molecule found in the tissues or fluids of your body that shows if a condition, process, or disease is normal or abnormal. Endometrial cancer may have a biomarker known as dMMR (mismatch repair deficient). Testing for this biomarker provides important information about your cancer and may help your doctor decide what treatment options, including JEMPERLI, may be right for you.